Tag Archives: Immunotherapy

Some Cancers Cloak Themselves from the Immune System’s Discovery

Some Cancers Cloak Themselves from the Immune System's Discovery
Some Cancers Cloak Themselves from the Immune System’s Discovery

Immunotherapy cancer treatment is designed to aid the body’s immune system in recognizing and attacking tumor cells. Scientists are finally uncovering clues as to how cancer cells are able to evade detection by the body’s natural defenses.

How Cancer Blocks the Immune System

The first steps were taken in 2009 by a team headed up by Dr. Irving Weissman, director of Stanford’s Institute for Stem Cell Biology and Regenerative Medicine. Their research discovered that some cancer cells are able to emit a “don’t eat me” signal.

High levels of CD47, a transmembrane protein, are found on the surface of more aggressive cancer cells. CD47 then binds with another protein called SIRPalpha on the surface of macrophages, a type of white blood cell, inhibiting their ability to attack cancer cells.

In 2017, Dr. Weissman’s team published the results of a recent study that identified another protein that interferes with macrophage activity. When MHC class 1 binds with a protein known as LILRB1, it’s resistant to an antibody that has been used successfully to counteract CD47 in tests on mice with cancer.

Applications for Immunotherapy Cancer Treatment

Cancer research is complicated by the fact that different types have different “fingerprints.” The studies conducted by Dr. Weissman’s team are helping scientists learn more about strategies to “outwit” cancer cells and their ability to avoid detection.

Issels®: Pioneering Immunotherapy Cancer Treatment

Our founder, Dr. Josef Issels, was ahead of his time in focusing on the immune system as the key to defeating advanced cancer. Contact us to learn more about how we are continuing his legacy of helping patients achieve long-term remission.

Molecularly Targeted Therapy Emerges As Another Possible Cancer Treatment

Molecularly Targeted Therapy Emerges As Another Possible Cancer Treatment
Molecularly Targeted Therapy Emerges As Another Possible Cancer Treatment

The problem with traditional cancer treatments is that they attack healthy cells along with diseased cells, which results in serious side effects such as fatigue and hair loss. Doctors are encouraged by the success of a new cancer treatment that zeroes in on the cancer cells.

The “Next Revolution in Cancer Therapy”

Molecularly targeted therapy is being hailed as the next big step in cancer treatment. These new drugs are designed at the molecular level to attack the diseased cells of a specific type of cancer. In addition, they can identify specific molecules that are part of specific cancers.

The drugs are created by a process that is the reverse of how most cancer drugs are developed. Scientists identify an abnormal molecule that’s unique to a particular type of cancer, then design a drug that shuts down its activity.

Gleevec: Paving the Way

Novartis Pharmaceuticals has developed Gleevec, also known as STI571, which is leading the way for molecularly targeted therapy. Gleevec is used for chronic myeloid leukemia, or CML, which is a rare form of the disease characterized by excessive production of white blood cells.

Researchers discovered that Gleevec is also effective against GIST, a rare gastrointestinal cancer. GIST features a unique enzyme related to the original target enzyme in CML.

State-of-the-Art Cancer Treatment at Issels®

Gene-targeted therapies, including Gleevec, Tamoxifen and Avastin, are a significant part of our personalized treatment programs. Issels® also uses non-toxic immunotherapy treatments that boost the immune system’s ability to target tumor cells.

Contact us today for more information about our decades of success in helping patients achieve long-term remission.

Breast Cancer Patients Treated with Combination Drugs Suffer More Side Effects

New Research for Breast Cancer Studies Genes
New Research for Breast Cancer Studies Genes

One of the concerns with traditional cancer treatment is the range and severity of potential side effects that may occur. Based on the results of a recent study, patients with advanced breast cancer who are treated with a certain combination of drugs are at greater risk for serious side effects.

Fighting Cancer on Two Fronts

Some breast cancers are classified as “hormone receptor-positive.” Signals from hormones such as estrogen and progesterone reach receptors in the cancer cells, triggering further growth. Patients are commonly treated with a receptor blocker such as tamoxifen in conjunction with drugs that specifically target molecules involved in cancer cell development.

Previous research indicated that this combination therapy enabled patients to live longer without progression of the tumors. The missing piece of the puzzle was the extent to which treatment could cause side effects.

Evaluating Side Effects of Combination Therapies

A study conducted by an international research team found that patients with combination therapy were more susceptible to side effects such as fatigue, diarrhea and hyperglycemia. The degree of risk varied based on the particular drugs involved.

Scientists plan to use these results to design courses of treatment that are less likely to produce side effects. In the meantime, since these therapies do have benefits, doctors will have more information to use in prescribing and managing combination drug treatments.

Issels® Leads the Way with Non-Toxic Cancer Treatment

Personalized cancer treatment at Issels® uses a patient’s own immune cells, reducing the risk of of debilitating side effects. Contact us to learn more about our cancer vaccines and other innovative treatment programs.

Immunotherapy and Its Use in Stage 2 and 3 Cancers

There is New Hope for Cancer Patients. Don't Give up!
There is New Hope for Cancer Patients. Don’t Give up!

Immunotherapy drugs have become a valuable weapon in the fight against metastatic cancer, also known as Stage 4. Researchers are discovering that immunotherapy for cancer treatment can also have positive results when used during earlier stages of the disease.

Immunotherapy and Early-Stage Cancer

At the recent European Society for Medical Oncology (ESMO) congress in Madrid, AstraZeneca presented successful trial results for its immuno-oncology drug Imfinzi in treating mid-stage lung cancer. AstraZeneca is considered a latecomer to the I-O field as compared to established companies such as Merck and Bristol-Meyers Squibb.

For their part, Bristol-Meyers produced evidence regarding Opdivo, the company’s widely used late-stage I-O drug. Opdivo has been shown to prevent relapses in melanoma patients when administered immediately post-surgery.

Supplementing Surgery with Immunotherapy

This method of following surgery with cancer treatment is referred to as adjuvant therapy. With the success of Opdivo, a number of trials are being conducted on adjuvant therapy using I-O drugs with a range of cancer types. Some trials are even focusing on neoadjuvant, or pre-surgery, treatment for breast, neck and head cancers.

What’s Next?

If the trend of early-stage immunotherapy treatment continues, early detection becomes even more important than ever. According to Pascal Soriot, CEO of AstraZeneca, effective early treatment is a powerful incentive for increased use of screening methods.

Non-Toxic Immunotherapy Programs from Issels®

Our cancer vaccines and other non-toxic, personally tailored immunotherapy treatment programs have resulted in long-term remission for patients with all types of therapy-resistant cancers. Contact us for more information about Issels®, the leader in immunotherapy for cancer treatment.

What Makes the Issels Immunotherapy Approach So Different?

Each Person is Different, and as a Result, so is Every Treatment Plan!
Each Person is Different, and as a Result, so is Every Treatment Plan!

Choosing a cancer treatment program can be the most important decision you’ll ever face. What makes the Issels® immunotherapy for cancer approach so different from traditional forms of cancer treatment?

Issels® Treatment Programs Are Individually Developed

Regardless of the type of cancer, each patient’s experience is unique. Our treatment programs are personally tailored to address a patient’s specific needs.

Issels® Therapies Are Created from a Patient’s Own Immune Cells

Issels® immunotherapy protocols boost your body’s immune response to use the power of your own natural defense mechanisms.

Issels® Immunotherapy Has No Adverse Side Effects

Immunotherapy is non-toxic and has less risk of side effects than traditional cancer treatments such as chemotherapy and radiation. Our immunotherapy programs should also be distinguished from pharmaceutically-developed immunotherapy drugs, which can trigger serious negative reactions.

Issels® Immunotherapy Programs Are Comprehensive

Focusing cancer treatment on one form can limit its impact on the disease. Our immunotherapy programs integrate a number of complementary elements that work together for greater effectiveness.

Issels® Treatment Programs Focus on Cancer and Its Environment

Destroying cancer cells is only part of the process. Our immunotherapy for cancer is also directed at altering the internal environment that promotes tumor growth.

Issels® Immunotherapy Is Not a Trial

Patients who participate in clinical trials may end up receiving a placebo. Our cancer vaccines and gene-targeted therapies have stood the test of time.

Experience the Issels® Difference

Want to learn more? Visit our website to read and hear testimonials from patients who have achieved years and decades of recurrence-free remission thanks to our Issels® immunotherapy for cancer programs.

What’s Happening in Colorectal Cancer Research?

 

Cancer Research is Making Progress Every Day. Here is the Latest for Colorectal Cancer.
Cancer Research is Making Progress Every Day. Here is the Latest for Colorectal Cancer.

Colorectal cancer is the third most common cancer diagnosed in the United States, but there are currently more than one million survivors in the country. The National Foundation for Cancer Research has some information you should know about this preventable disease.

Rates and Risks of Colorectal Cancer

• Overall risks of developing colorectal cancer are marginally higher for men. Approximately one in 21 is diagnosed with the disease, while the numbers for women are one in 23.

• Health factors that increase the risk of colorectal cancer include inflammatory bowel disorders, family history and genetics, and personal history of polyps or another form of cancer.

• Poor lifestyle choices such as smoking, obesity and high-fat diets, heavy alcohol use and physical inactivity also contribute to colorectal cancer risk.

Regular screenings can help prevent colorectal cancer.

Colorectal Cancer Research in the News

Genomics and immunotherapy for cancer are the main focus points of today’s colorectal cancer research.

• Dr. Wei Zhang and his NFCR-funded team are continuing their promising studies into biomarkers and their use in improving colorectal cancer prognosis and predicting responses to treatment.

• NFCR has also supported the work of Dr. Yung-Chi Cheng, who is on the cusp of producing one of the first FDA-approved oral herbal immunotherapies for cancer. When applied in combination with chemotherapy, PH906 has been found to ease gastrointestinal side effects that accompany treatment for colon and rectal cancers.

Personally Developed Immunotherapy for Cancer at Issels®

Our integrative, non-toxic cancer treatment programs are powerful and effective, but they avoid the often painful side effects of traditional treatments. Contact us for more information.